486 related articles for article (PubMed ID: 36494005)
1. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
[TBL] [Abstract][Full Text] [Related]
2. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
4. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
5. Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma.
Medikonda R; Choi J; Pant A; Saleh L; Routkevitch D; Tong L; Belcaid Z; Kim YH; Jackson CM; Jackson C; Mathios D; Xia Y; Shah PP; Patel K; Kim T; Srivastava S; Huq S; Ehresman J; Pennington Z; Tyler B; Brem H; Lim M
J Neurosurg; 2022 Feb; 136(2):379-388. PubMed ID: 34388730
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
[TBL] [Abstract][Full Text] [Related]
7. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
8. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
10. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
12. Autophagy-related gene expression classification defines three molecular subtypes with distinct clinical and microenvironment cell infiltration characteristics in colon cancer.
Zhu S; Wu Q; Zhang B; Wei H; Li B; Shi W; Fang M; Zhu S; Wang L; Lang Zhou Y; Dong Y
Int Immunopharmacol; 2020 Oct; 87():106757. PubMed ID: 32769067
[TBL] [Abstract][Full Text] [Related]
13. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Job S; Rapoud D; Dos Santos A; Gonzalez P; Desterke C; Pascal G; Elarouci N; Ayadi M; Adam R; Azoulay D; Castaing D; Vibert E; Cherqui D; Samuel D; Sa Cuhna A; Marchio A; Pineau P; Guettier C; de Reyniès A; Faivre J
Hepatology; 2020 Sep; 72(3):965-981. PubMed ID: 31875970
[TBL] [Abstract][Full Text] [Related]
14. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract][Full Text] [Related]
15. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
Koch MS; Zdioruk M; Nowicki MO; Griffith AM; Aguilar E; Aguilar LK; Guzik BW; Barone F; Tak PP; Tabatabai G; Lederer JA; Chiocca EA; Lawler S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017150
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
Zhang J; Xiao X; Zhang X; Hua W
J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
[TBL] [Abstract][Full Text] [Related]
17. Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma.
Choi J; Medikonda R; Saleh L; Kim T; Pant A; Srivastava S; Kim YH; Jackson C; Tong L; Routkevitch D; Jackson C; Mathios D; Zhao T; Cho H; Brem H; Lim M
Oncoimmunology; 2021; 10(1):1956142. PubMed ID: 34484870
[TBL] [Abstract][Full Text] [Related]
18. The short isoform of MS4A7 is a novel player in glioblastoma microenvironment, M2 macrophage polarization, and tumor progression.
Ni B; Huang G; Yang R; Wang Z; Song H; Li K; Zhang Y; Wu K; Shi G; Wang X; Shen J; Liu Y
J Neuroinflammation; 2023 Mar; 20(1):80. PubMed ID: 36944954
[TBL] [Abstract][Full Text] [Related]
19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
20. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
[Next] [New Search]
